Clinical trials: Recurrent Endometrial Carcinoma
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Gynecologic Cancer, Carcinoma
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing.
- Conditions
- Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
- Trial name
- NCT05559879
- Testing
- Cabo + Dostarlimab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Alabama at Birmingham
Endometrial Cancer
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line…
- Trial name
- DUOLife (NCT06890273)
- Where
- 49 sites in Germany
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Endometrial Cancer, Sarcoma
Thalidomide in Treating Patients With Gynecologic Sarcomas
RATIONALE: Thalidomide may stop the growth of gynecologic sarcomas by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent…
- Trial name
- NCT00006005
- Testing
- thalidomide
- Where
- 10 sites in United States
- Sponsor
- New York University Cancer Institute
Recurrent or Metastatic Endometrial Cancer
QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer
the investigators planned to evaluate the efficacy and safety of QL1706 in combination with chemotherapy as first-line systemic therapy in approximately 26 patients with newly diagnosed recurrent or metastatic endometrial cancer…
- Trial name
- NCT06751277
- Testing
- QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
- Where
- China
- Volunteers
- 26 people
- Sponsor
- xiang yang
Endometrial Cancer
Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating women who have…
- Trial name
- NCT00005861
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- 10 sites in United States
- Sponsor
- Gynecologic Oncology Group
Endometrial Neoplasms
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
- Trial name
- NCT01420081
- Testing
- PF-05212384
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Pfizer
Endometrial Cancer
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006377
- Testing
- carboplatin, doxorubicin hydrochloride, paclitaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Endometrial Cancer
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab in women with advanced, recurrent or persistent endometrial cancer.
- Trial name
- NCT03526432
- Testing
- Bevacizumab, Atezolizumab
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- University of Oklahoma
Cervical Cancer, Endometrial Cancer
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
This research study is evaluating a drug called avastin in combination with standard radiation as a possible treatment for treatment for recurrent pelvic-confined gynecological cancer (i.e.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
- Trial name
- NCT00545792
- Testing
- Avastin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Cancer, Kidney Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Kidney Cancer, Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00002764
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- Sweden
- Volunteers
- 340 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Endometrial Cancer
Atezolizumab Trial in Endometrial Cancer - AtTEnd
Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1.
- Trial name
- AtTEnd (NCT03603184)
- Testing
- Atezolizumab, Paclitaxel, Carboplatin
- Where
- 93 sites in Australia, Austria and 9 more
- Volunteers
- 549 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Endometrial Neoplasms
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
To test the patient's cancerous tumor to see if it has a FGFR mutation and, if so, to see how their cancer responds to a treatment with the drug ponatinib as well as examine the side effects caused by ponatinib.
- Trial name
- NCT01888562
- Testing
- Ponatinib
- Sponsor
- Washington University School of Medicine
Ovarian Neoplasms, Endometrial Neoplasms
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer
- Trial name
- DOVE (NCT06023862)
- Testing
- Dostarlimab, Bevacizumab, Doxorubicin
- Where
- 27 sites in Australia, Hong Kong and 5 more
- Volunteers
- 198 people
- Sponsor
- Yonsei University
Endometrial Cancer
Study of EV for Recurrent Endometrial Carcinoma
This study is testing a drug called enfortumab vedotin in up to 12 patients with advanced endometrial (uterine) cancer that has worsened after previous treatments, including immunotherapy.
- Trial name
- EV-4-EC (NCT07139977)
- Testing
- Enfortumab Vedotin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- William Bradley
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial studies the side effects and how well cediranib maleate works in treating patients with endometrial cancer that has failed to respond to initial chemotherapy or has come back after surgery, radiation therapy…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01132820
- Testing
- Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 87 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains…
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT05554328
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 295 sites in United States, Puerto Rico
- Volunteers
- 165 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Non Endometrioid Carcinoma, Endometrioid Carcinoma
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
The aim of this trial is to evaluate the sentinel node policy in early stage endometrial carcinomas at intermediate and high risk of recurrence (by comparing the sentinel node policy to current initial staging protocols).
- Trial name
- SENTIRAD (NCT02598219)
- Testing
- Pre-operative SN mapping with radionucleide, Intra-operative SN mapping with patent V blue dye, Intra-operative SN mapping with indocyanin green
- Where
- 16 sites in France
- Volunteers
- 262 people
- Sponsor
- Centre Oscar Lambret